<DOC>
	<DOC>NCT02624141</DOC>
	<brief_summary>This study will examine the efficacy, safety, and effect on hemoglobin levels, of once weekly epoetin beta subcutaneous injections (30,000 International Units [IU]) in anemic patients with solid tumors. The anticipated study duration is 4 months, and the target sample size is 40 individuals.</brief_summary>
	<brief_title>A Study of Recormon (Epoetin Beta) in Anemic Patients With Non-Myeloid Malignancy</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Adult patients with a nonmyeloid malignancy Anemia Transfusion of red blood cells within 2 months of study drug Treatmentresistant hypertension Acute or chronic bleeding (requiring therapy) within 3 months of study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>